Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.
On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...
2seventy bio (NASDAQ:TSVT) just reported results for the first quarter of 2024. 2seventy bio reported earnings per share of ...
CAMBRIDGE, Mass., August 29, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd ...
Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $5.05 which represents a slight increase of $0.18 or 3.70% from the prior close of $4.87. The stock opened at $4.79 and touched a ...
Investors in 2seventy bio, Inc. TSVT need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $2.50 Call had some of the highest ...
In a report released on August 7, Daina Graybosch from Leerink Partners maintained a Buy rating on 2seventy bio (TSVT – Research Report). The company’s shares closed yesterday at $4.56.
CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
The market expects 2seventy bio, Inc. (TSVT) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback